Tissue Transglutaminase (tTG) Antibody, IgA
Celiac disease (CD) (also known as gluten-sensitive enteropathy (GSE) or celiac sprue) is a genetic, inheritable disease that manifests itself as a chronic malabsorptive autoimmune disorder of the small intestine. It is thought that this disease affects 1:1750 to 1:150 people in the United States. The abnormal mucosal immune response associated with the disease is activated by the interaction of gliadin from wheat, barley, or rye with genetically susceptible people with the HLA-DQ2 or HLA-DQ8 allelic variants of the human leukocyte molecule. Over 96% of patients have one or both of these HLA variants. Inflammation in the small intestine results in atrophy of the mucosal surface villi leading to loss of ability to absorb nutrients. Cinical symptoms include diarrhea, constipation, abdominal pain and malabsorption. Manifestations outside of the gastrointestinal tract include iron deficiency anemia, chronic fatigue, failure to grow and thrive, delayed puberty, short stature, dermatitis herpetiformis, recurrent fetal loss, osteoporosis, dental enamel loss, frequent aphthous stomatitis, and neurologic symptoms including ataxia and peripheral neuropathy. Patients are at risk of developing malignant lymphoma as well. Patients have a higher frequency of diabetes mellitus, IgA deficiency, Down syndrome and thyroiditits. Definitive diagnosis of this disorder requires small intestine biopsy, an invasive procedure. Therefore, to reduce the need for this procedure, patients with appropriate clinical symptoms undergo blood testing for abnormalities such as the presence of tissue transglutaminase antibody and others, and only those patients with abnormal values are then referred for small intestine biopsy.
The protein cross-linking enzyme, tissue transglutaminase (tTG), was recently discovered to be the major antigen to which the celiac patient’s autoantibodies are directed. Once tTG deaminates gliadin, a tTG-Gliadin complex forms. This complex stimulates the body’s defenses to produce the anti-tTG antibodies causing symptoms such as abdominal pain, weight loss, diarrhea, failure to thrive (in children), or other more elusive symptoms. Antibodies are usually of the IgA isotype, which is why testing for IgA antibody must be included in testing. A lesser amount of IgG antibody is also produced, especially in IgA-deficient patients. The best tests are anti-tTG and anti-deaminated gliadin.
This anti-tTG assay provides a noninvasive testing methodology to be used in conjunction with other serologic assays to screen for the presence of antibodies associated with celiac disease. Treatment of GSE consists of a gluten-free diet. Patients who adhere to this diet show marked improvement of symptoms, decrease in anti-tTG and anti-deaminated gliadin antibodies and regeration of small intestine mucosa.
- Aid in diagnosis and treatment of celiac disease
- Evaluation of patients with family history of gluten-sensitive enteropathy
- Monitoring for maintenance of a gluten-free diet
- As an aid in diagnosis of dermatitis herpetiformis
- Differential diagnosis of irritable bowel syndrome
Increased in:
- Celiac disease
- Dermatitis herpetiformis, some
- Irritable bowel syndrome
- Inflammatory bowel disease
Negative (Non-reactive)
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (SST) or plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
1-3 days.
- Neurochem Int. 2002 Jan;40(1):79-83. [PMID: 11738474]
- Gastroenterol Clin North Am. 2003 Sep;32(3):931-47. [PMID: 14562582]
- Eur Ann Allergy Clin Immunol. 2005 Dec;37(10):397-403. [PMID: 16528904]
- Front Biosci. 2006 Jan 1;11:249-55. [PMID: 16146729]
- Gastroenterol (National Institute of Health). 128 (4 Suppl 1): 2005.02.030. [PMID: 15825126]